Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
Syndax Pharmaceuticals (SNDX) has announced an upcoming investor event scheduled for December 9, 2024, at 7:00 a.m. PT/10:00 a.m. ET during the 66th American Society of Hematology Annual Meeting in San Diego. The event will be held both in-person and via webcast.
The company's management team will collaborate with key opinion leaders to present updates on their revumenib and Niktimvo™ (axatilimab-csfr) programs. Interested parties can access the live webcast through the Investor section of Syndax's website, where a recording will also be available temporarily.
Syndax Pharmaceuticals (SNDX) ha annunciato un prossimo evento per gli investitori programmato per il 9 dicembre 2024, alle 7:00 PT/10:00 ET, durante la 66ª Riunione Annuale della Società Americana di Ematologia a San Diego. L'evento si terrà sia in presenza sia tramite webcast.
Il team di gestione dell'azienda collaborerà con i principali esperti per presentare aggiornamenti sui loro programmi di revumenib e Niktimvo™ (axatilimab-csfr). Le parti interessate possono accedere al webcast dal vivo tramite la sezione Investitori del sito web di Syndax, dove sarà anche disponibile temporaneamente una registrazione.
Syndax Pharmaceuticals (SNDX) ha anunciado un próximo evento para inversores programado para el 9 de diciembre de 2024, a las 7:00 a.m. PT/10:00 a.m. ET, durante la 66ª Reunión Anual de la Sociedad Americana de Hematología en San Diego. El evento se realizará tanto de manera presencial como a través de webcast.
El equipo de gestión de la empresa colaborará con líderes de opinión clave para presentar actualizaciones sobre sus programas de revumenib y Niktimvo™ (axatilimab-csfr). Las partes interesadas pueden acceder al webcast en vivo a través de la sección de Inversores del sitio web de Syndax, donde también estará disponible temporalmente una grabación.
신닥스 제약(Syndax Pharmaceuticals) (SNDX)는 2024년 12월 9일 오전 7시 PT/오전 10시 ET에 샌디에고에서 열리는 제66회 미국 혈액학회 연례 회의에서 예정된 투자자 행사를 발표했습니다. 이 행사는 대면 및 웹캐스트 방식으로 진행됩니다.
회사의 경영팀은 주요 의견 리더들과 협력하여 레부미닙(revumenib)과 닉팀보™(Niktimvo™, axatilimab-csfr) 프로그램에 대한 업데이트를 발표할 것입니다. 관심 있는 분들은 신닥스 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있으며, 해당 녹화도 일시적으로 제공될 예정입니다.
Syndax Pharmaceuticals (SNDX) a annoncé un prochain événement pour les investisseurs prévu pour le 9 décembre 2024, à 7h00 PT/10h00 ET, lors de la 66e Réunion Annuelle de la Société Américaine d'Hématologie à San Diego. L'événement se tiendra à la fois en personne et par webcast.
L'équipe de direction de l'entreprise collaborera avec des leaders d'opinion clés pour présenter des mises à jour sur leurs programmes de revumenib et Niktimvo™ (axatilimab-csfr). Les parties intéressées peuvent accéder au webcast en direct via la section Investisseurs du site Web de Syndax, où un enregistrement sera également disponible temporairement.
Syndax Pharmaceuticals (SNDX) hat ein bevorstehendes Investorenevent angekündigt, das für den 9. Dezember 2024, um 7:00 Uhr PT/10:00 Uhr ET, während der 66. Jahrestagung der American Society of Hematology in San Diego geplant ist. Die Veranstaltung wird sowohl persönlich als auch über einen Webcast stattfinden.
Das Management-Team des Unternehmens wird mit wichtigen Meinungsführern zusammenarbeiten, um Updates zu ihren Revumenib- und Niktimvo™ (Axatilimab-csfr)-Programmen zu präsentieren. Interessierte Parteien können über den Bereich Investoren auf der Website von Syndax auf den Live-Webcast zugreifen, wo auch eine Aufzeichnung vorübergehend verfügbar sein wird.
- None.
- None.
A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-to-host-ash-investor-event-in-person-and-via-webcast-on-december-9-2024-302295973.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When is Syndax's (SNDX) ASH investor event scheduled for 2024?
What programs will be discussed at Syndax's (SNDX) December 2024 investor event?
How can investors access Syndax's (SNDX) ASH 2024 investor event?
Where will Syndax's (SNDX) December 2024 investor event be held?
